A novel Keap1-Nrf2 inhibitor 6K delays the progression of AKI-to-CKD by mitigating maladaptive repair
Yiming Wang, Yi Sun, Ting Zhou, Cai Gao, Jihan Liu, Zhicong Chen, PanShuang Qiao, Guangying Shao, Min Li, Baoxue Yang, Chunlin Zhuang, Hong Zhou · 2026
Read A novel Keap1-Nrf2 inhibitor 6K delays the progression of AKI-to-CKD by mitigating maladaptive repair by Yiming Wang, Yi Sun, Ting Zhou, Cai Gao, Jihan Liu, Zhicong Chen, PanShuang Qiao, Guangying Shao, Min Li, Baoxue Yang, Chunlin Zhuang, Hong Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579313.txt.
Description
Wang and a team of colleagues tested a new kidney-protective compound in twenty twenty-six. Severe acute kidney injury often heals badly, leaving scarring that becomes chronic kidney disease. A repair program in tubule cells can turn maladaptive, driven by oxidative stress and an iron-linked cell death called ferroptosis. A master switch, Nrf2, normally defends cells against both.
Mice lacking Nrf2 developed worse scarring and more stress and death markers after blood-flow injury. The compound 6K frees Nrf2 from its keeper protein, Keap1. Treated mice kept better kidney function, showed less oxidative damage and ferroptosis, and shifted repair genes toward healthy patterns. In human kidney cells, 6K restored a key protective enzyme and cut lipid damage. Fibrosis also slowed in a second injury model. The authors propose 6K as a kidney-targeted drug candidate.
Catalog record
| CREATOR | Yiming Wang, Yi Sun, Ting Zhou, Cai Gao, Jihan Liu, Zhicong Chen, PanShuang Qiao, Guangying Shao, Min Li, Baoxue Yang, Chunlin Zhuang, Hong Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |